View Post

Findings About Children’s Solid Tumors Are Sparking New Therapies

In Clinical Trials by Barbara Jacoby

By: Beth Fand Incollingo From: curetoday.com Compared with solid tumors in adults — about which scientists are learning more and more — those that occur in children are mysteries. Not only are pediatric tumors rare, but they arise in developing tissues, making them difficult to study and treat. That’s where the Childhood Solid Tumor Network (CSTN), run by St. Jude …

View Post

Lilly’s CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Global, randomized, placebo-controlled study confirms CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations Global regulatory submissions to be initiated this year  Second positive Phase 3 study of CYRAMZA in metastatic non-small cell lung cancer Eli Lilly and Company (NYSE: LLY) today …

View Post

Merck’s Keytruda set to become new standard of care for renal cancer patient population after gaining edge over competitors

In Clinical Trials by Barbara Jacoby

From: globaldata.com Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combination with Pfizer’s Inlyta, a tyrosine kinase inhibitor, can significantly improve clinical outcomes for renal cancer patients. Amrita Gujral, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the …

View Post

Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

In Clinical Trials by Barbara Jacoby

Source: Celsion CORP From: globenewswire.com Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the oral presentation of data highlighting the safety, clinical response and translational data from its recently completed OVATION I Study. This Phase IB study evaluated patients newly diagnosed with Stage III/IV ovarian cancer and were treated with Celsion’s DNA-based, IL-12 immunotherapy, GEN-1, in combination …

View Post

Radiation after surgery triples survival for a type of pediatric brain tumor

In Clinical Trials by Barbara Jacoby

By: St. Jude Children’s Research Hospital From: medicalxpress.com Radiation immediately following surgery in children with ependymoma, the third most common pediatric brain tumor, can nearly triple survival. The results are part of a Children’s Oncology Group (COG) clinical trial led by Thomas E. Merchant, D.O., Ph.D., of St. Jude Children’s Research Hospital. The findings appear as an advance online publication …

View Post

Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

In Clinical Trials by Barbara Jacoby

From: mesothelioma.net An exciting new immunotherapy treatment is now being tested in a phase I clinical trial that is still recruiting for participants. This provides a unique opportunity for patients who qualify to get access to an innovative medicine with great promise. Known as CAR T-cell therapy, this new treatment uses gene therapy to modify a patient’s immune system cells. …

View Post

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer

In Clinical Trials by Barbara Jacoby

By: Bradley J. Monk, MD From: onclive.com The treatment of women with advanced-stage epithelial ovarian cancer (EOC) is aggressive surgical cytoreduction and platinum-based combination chemotherapy. The timing and the extent of surgery have direct implications on the selection of subsequent treatment of patients with EOC. Frontline chemotherapeutic regimens have evolved through a series of large multi-institutional randomized clinical trials that …

View Post

Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab

In Clinical Trials by Barbara Jacoby

At ASCO-SITC Clinical Immuno-Oncology Symposium From: digitaljournal.com – Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy – Median overall survival not yet reached with median follow up of 14.4 months in Cohort A – Improved survival observed in patients with low CD8+ “cold” tumor at baseline …

View Post

DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

In Clinical Trials by Barbara Jacoby

From: financialbuzz.com DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme (GBM) has achieved its halfway enrollment point. This trial, targeted to enroll up to thirty patients, is a single-arm, open-label study …

View Post

Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

In Clinical Trials by Barbara Jacoby

Source: Immatics From: pipelinereview.com Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced / metastatic solid tumors. IMA101 is based on Immatics’ ACTolog® approach, which follows …